UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	690022.527C4
First Inventor	Scott S. Graves
Title	HUMANIZED ANTIBODIES THAT BIND TO THE ANTIGEN BOUND BY ANTIBODY NR-LU-13 AND THEIR USE IN PRETARGETING METHODS
Express Mail Label No.	EV336652109US

APPLICATION ELEMENTS			ADDRESS TO: Mail Stop Patent Application Commissioner for Patents P.O. Box 1450			
See MPEP chapter 600	concerning utility patent application contents.		Alexandria, VA 22313-1450 87			
(Submit an o	mittal Form (e.g., PTO/SB/17) original and a duplicate for fee processing) claims small entity status.		 7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence 			
See 37 CF			Submission (if applicable, all necessary)			
- Descriptive - Cross Refe	on [Total Pages74] arrangement set forth below) title of the Invention erence to Related Applications Regarding Fed sponsored R & D		 a.			
- Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. Drawing(s) (35 U.S.C. 113) [Total Sheets 35] 5. Supplemental Declaration [Total Sheets 10] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76			ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. 37 CFR 3.73(b) Statement Power of (when there is an assignee) Attorney 11. English Translation Document (if applicable) 12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other: Copy of Assignment Copy of Declaration re ATCC Deposit			
		Copy of Ext. of Time Petition for parent appln.				
18. If a CONTINUING APPLICATION OR APPLICATION CLAIMING FOREIGN PRIORITY, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: ☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) ☐ Claims priority from U.S. Patent Application No. 10/056,794 filed 01/24/02 Prior application information						
	Correspondence address below	<u> </u>	or:			
Firm Name	Correspondence address below		Customer Number			
Address			Customer Number			
City, State, Zip		00500				
Country		00500				
Telephone (206) 622-4900 Fax		x	(206) 682-6031			
Name (Print/Type)	Richard G. Sharkey, Ph.D.		Registration No. (Attorney/Agent) 32,629			
Signature	Roll of Maly		Date February 25, 2004			
			MillicentS/459302			

FEB 2 5 2004 4

ETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136	
	/~ \
ETHION FOR EXTENSION OF THIS UNDER 37 CFR 1.130	C I

Docket Number 690022.527C2

		In re Application of Scott S. Graves, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Stephen M.J. Searle, Andrew H. Henry, Jan T. Pedersen and Anthony R. Rees				
		Application Number 10/056,794		Filed January 24, 2002		
				ENICITY OR TOXICITY		
			OF IgG CLASS (AS			
		Art Unit 1642	Examiner BLANCHARD, Dav	vid J.		
	s is a request unde ly in the above ider	r the provisions of 37 CFR 1 ntified application.				
	e requested extensi eck time period des	on and appropriate non-sma	ill-entity fee are as follo	ws		
	One mo	onth (37 CFR 1.17(a)(1))	•	\$		
	Two mo	onths (37 CFR 1.17(a)(2))		\$		
	▼ Three r	nonths (37 CFR 1.17(a)(3))		. \$ <u>950</u>		
	Four m	onths (37 CFR 1.17(a)(4))		\$		
	Five mo	onths (37 CFR 1.17(a)(5))		\$		
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ A check in the amount of the fee is enclosed. Payment by credit card. Form PTO-2038 is attached. The Director has already been authorized to charge fees in this application to a Deposit Account. The Director is hereby authorized to charge any fees which may be required or credit any overpayment, to Deposit Account Number 19-1090.						
l an	n the [] applicant/in	ventor.				
assignee of record of the entire interest. See 37 CFR 3.71						
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
attorney or agent of record. Registration No. 32,629						
attorney or agent under 37 CFR 1.34(a).						
	Registra	tion number if acting under 37 CFR	1.34(a)			
W. be	ARNING: Informate included on this	tion on this form may beco form. Provide credit card	me public. Credit car information and auth	rd information should not orization on PTO-2038.		
	2/25/0	4	hund	Merly		
	Date		· S	ignature ³		
	206-622-4			Sharkey, Ph.D.		
NOTE:	Telephone Nur Signatures of all the			or printed name		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						

Oct

MillicentS/459048